Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04325893
Other study ID # 49RC20_0071
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date April 1, 2020
Est. completion date June 18, 2020

Study information

Verified date April 2020
Source University Hospital, Angers
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A new human coronavirus responsible for pneumonia, SARS-CoV-2, emerged in China in December 2019 and has spread rapidly. COVID-19, the disease caused by this virus, has a very polymorphous clinical presentation, which ranges from upper respiratory tract infections to acute respiratory distress syndrome. It may appear serious straightaway or may evolve in two stages, with a worsening 7 to 10 days after the first clinical signs, potentially linked to a cytokine storm and accompanied by a high risk of thrombosis. The global mortality rate of COVID-19 is between 3% and 4%, with severe forms being more frequent among older patients. Management is symptomatic as no antiviral treatment has demonstrated any clinical benefit in this condition. Hydroxychloroquine is a derivative of chloroquine commonly used in some autoimmune diseases, such as systemic lupus erythematosus. It is active in vitro in cellular models of infection by many viruses such as HIV, hepatitis C or SARS-CoV. However, its interest in viral infections in humans has not been demonstrated.

Very recently, a preliminary uncontrolled study evaluated the effect of hydroxychloroquine on viral shedding in subjects with COVID-19. Among 20 patients treated with hydroxychloroquine at a dose of 600 mg per day, the percentage of patients with detectable SARS-CoV-2 RNA in the nasopharynx decreased from 100% at inclusion (start of treatment) to 43% six days later. In comparison, 15 of 16 untreated patients had a positive RT-PCR six days after inclusion. Furthermore, hydroxychloroquine has immunomodulating and anti-inflammatory properties, which could theoretically prevent or limit secondary worsening.

The research hypothesis is that treatment with hydroxychloroquine improves prognosis and reduces the risk of death or use for invasive ventilation in patients with COVID-19.


Recruitment information / eligibility

Status Terminated
Enrollment 259
Est. completion date June 18, 2020
Est. primary completion date June 18, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years old

- Symptomatic infection with COVID-19 confirmed by positive RT-PCR SARS-CoV-2 or, failing that, by thorax CT-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context.

- Diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days.

- Patient having at least one of the following risk factors for developing complications:

- Age =75 years old

- Age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index = 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment

- Need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (SpO2 > 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmHg (PaO2/FiO2 = 300 mmHg).

- Patient affiliated to a social security scheme.

- Written and signed consent of the patient or a relative or emergency inclusion procedure.

Exclusion criteria

- Last RT-PCR negative for SARS-CoV-2

- Peripheral capillary oxygen saturation less than or equal to 94% (SpO2 = 94%) despite oxygen therapy greater than or equal to 3 L/min (> 3 L/min)

- Organ failure requiring admission to a critical or intensive care unit.

- Comorbidity that is life threatening in the short-term (life expectancy < 3 months)

- Any reason that makes patient follow-up throughout the study impossible

- Current treatment with hydroxychloroquine

- Absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria)

- Hypokalaemia < 3.5 mmol/L

- Corrected QT prolongation (QTc = 440 ms in men and 460 ms in women).

- Child-Pugh's class C liver cirrhosis

- Chronic kidney failure with estimated GFR = 30 ml/min, or = 40 ml/min in patients with concomitant treatment with azithromycin

- Women who are pregnant, breastfeeding, or parturient

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxychloroquine
First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
Placebo
TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.

Locations

Country Name City State
France CH Agen Agen
France CHU Amiens Amiens
France CHU Angers Angers
France CH Auxerre Auxerre
France APHP Avicenne Bobigny
France CHU Brest Brest
France CHU Caen Caen
France CH Chalon Sur Saône Chalon Sur Saône
France CH Cherbroug Cherbourg
France CH Cholet Cholet
France CH Colmar Colmar
France CH Compiègne Compiègne
France APHP Henri Mondor Créteil
France CH Intercommunal Créteil Créteil
France CHU Dijon Dijon
France APHP Joffre Dupuytren Draveil
France CHD Vendée La Roche-sur-Yon
France CH Laval Laval
France CH Le Mans Le Mans
France CH Emile Roux Le Puy-en-Velay
France APHP Emile ROUX Limeil-Brevannes
France CHU Limoges Limoges
France CH Lorient Lorient
France Hôpital Européen - Marseille Marseille
France Hôpital Saint-Joseph Marseille
France CH Melun Melun
France CHU Nantes Nantes
France Hôpital Privé du Confluent Nantes
France CH Niort Niort
France CHR Orléans Orléans
France APHP Saint-Antoine Paris
France GH Croix Saint Simon Paris
France La Pitié-Salpétrière Paris
France CHU Poitiers Poitiers
France CH Pointoise Pontoise
France CH Quimper Quimper
France CH Saint-Brieuc Saint-Brieuc
France CHU Saint-Etienne Saint-Étienne
France CH Saint-Nazaire Saint-Nazaire
France CHU Toulouse Toulouse
France CH Tourcoing Tourcoing
France CHU Tours Tours
France CH Valenciennes Valenciennes
France Clinique Tessier Valenciennes Valenciennes
France CH Vannes Vannes
France CH Versailles Versailles
Monaco CH Princesse Grace Monaco

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Countries where clinical trial is conducted

France,  Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment. Day 14
Secondary Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment. Day 28
Secondary Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14 WHO Ordinal Scale for Clinical Improvement ranges from 0 to 8, higher score meaning poorer outcome Day 14
Secondary Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28. WHO Ordinal Scale for Clinical Improvement ranges from 0 to 8, higher score meaning poorer outcome Day 28
Secondary Number of all-cause mortality at day 14 Day 14
Secondary Number of all-cause mortality at day 28 Day 28
Secondary Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5 Day 5
Secondary Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10 Day 10
Secondary The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee. Day 28
Secondary Number of all-cause mortality at day 28 in patients aged 75 and older day 28
Secondary Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older day 28
Secondary Rate of severe adverse events at day 28 day 28
Secondary Number of all-cause mortality at day 14 in patients aged 75 and older day 14
See also
  Status Clinical Trial Phase
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT05359770 - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19 N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Not yet recruiting NCT06025812 - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) N/A
Recruiting NCT05289115 - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS N/A
Completed NCT04953078 - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 Phase 1
Completed NCT04779138 - Increasing Vaccine Uptake in Underresourced Public Housing Areas N/A
Not yet recruiting NCT05868239 - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study N/A
Completed NCT04818164 - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04572399 - UVA Light Device to Treat COVID-19 N/A
Recruiting NCT04610567 - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) Phase 1/Phase 2
Recruiting NCT04772170 - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting NCT04581954 - Inflammatory Signal Inhibitors for COVID-19 (MATIS) Phase 1/Phase 2
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Completed NCT05572840 - Wear Your Mask, Wash Your Hands, Don't Get COVID-19 N/A
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3